← Back to Analyst Consensus 
INMB Buy
Inmune Bio, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Mar 11, 2026 | LUCID CAPITAL MARKETS | upgrade | Neutral → Buy | — | 32% |
| Jul 2, 2025 | Maxim Group | maintain | Buy → Buy | $8 | 42% |
| Jul 1, 2025 | BTIG | downgrade | Buy → Neutral | $0 | 52% |
| Jul 1, 2025 | Scotiabank | downgrade | Sector Outperform → Sector Underperform | $0.6 | 55% |
| Feb 13, 2025 | Maxim Group | maintain | Buy → Buy | $30 | 42% |
| Feb 11, 2025 | Scotiabank | maintain | Sector Outperform → Sector Outperform | $23 | 55% |
| Jun 1, 2023 | Baird | initiate | — → Outperform | $16 | 55% |
| May 24, 2022 | BTIG | maintain | — → Buy | $14 | 52% |
| May 24, 2022 | B. Riley Securities | downgrade | Buy → Neutral | $7 | 55% |
| Jan 24, 2022 | B. Riley Securities | maintain | — → Buy | $20 | 55% |
| Apr 21, 2021 | B. Riley Securities | initiate | — → Buy | $29 | 55% |
| Nov 9, 2020 | HC Wainwright & Co. | maintain | — → Buy | $15 | 44% |
| Sep 1, 2020 | BTIG | initiate | — → Buy | $23 | 52% |
| Jul 15, 2020 | HC Wainwright & Co. | maintain | — → Buy | $20 | 44% |
| May 15, 2020 | HC Wainwright & Co. | reiterate | — → Buy | $8 | 44% |
| Mar 12, 2020 | HC Wainwright & Co. | maintain | — → Buy | $8 | 44% |
| Dec 19, 2019 | Roth Capital | initiate | — → Buy | $13 | 53% |
| Aug 21, 2019 | HC Wainwright & Co. | initiate | — → Buy | $11.5 | 44% |
| Mar 19, 2019 | Maxim Group | initiate | — → Buy | $0 | 42% |
Price Target Trend
Mar 30, 2026 Latest: $7 Oct 24, 2026
EPS Estimates
+1q $-0.21
Lo: $-0.21 Hi: $-0.21
1 analysts ▲1
+1y $-0.43
Lo: $-0.43 Hi: $-0.43
1 analysts ▲1
0q $-0.20
Lo: $-0.20 Hi: $-0.20
1 analysts ▲1
0y $-0.67
Lo: $-0.67 Hi: $-0.67
1 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days